Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This clinical trial is studying the drug Ribociclib (LEE011) in combination with an
immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control
cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative
breast cancer (in combination with fulvestrant) or metastatic epithelial ovarian cancer.
The names of the medications involved in this study are:
- Ribociclib (LEE011)
- PDR001
- Fulvestrant